Advertisement

Radikale Prostatektomie beim Prostatakarzinom im Stadium D1 (T0–3, N1–2, M0)

  • R. C. Benson
  • H. Zincke
Conference paper

Zusammenfassung

Das Adenokarzinom der Prostata ist gegenwärtig mit annähernd 100000 Neuerkrankungen pro Jahr und 30000 Todesfällen der am weitesten verbreitete Krebs unter amerikanischen Männern. Durch eine Änderung des Konzeptes der chirurgischen Behandlung bei dieser Erkrankung sind bis zu 30% der am Prostatakarzinom erkrankten Patienten potentielle Kanditaten für eine definitive Operation, wie z. B. die radikale Prostatektomie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Whitmore WF jr (1987) Long-term effects of initial therapy. Cancer 60 [Suppl] 3: 559–562Google Scholar
  2. 2.
    Kuban DA, El-Mandi AM, Schellhammer PF (1987) Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 30: 420–426PubMedCrossRefGoogle Scholar
  3. 3.
    Zincke H, Utz DC, Thule PM, Taylor WF (1987) Treatment options for patients with stage D1 (T0–3, N1–2, MO) adenocarcinoma of prostate. Urology 30: 307–315PubMedCrossRefGoogle Scholar
  4. 4.
    Bagshaw MA, Ray GR, Cox RS (1985) Radiotherapy of prostatic carcinoma: Long-or short-term efficacy (Stanford University experience). Urology 25 [Suppl] 2: 17–23Google Scholar
  5. 5.
    Zincke H, Fleming TR, Furlow WL, Myers RP, Utz DC (1981) Radical retropubic prostatectomy and pelvic lymphadenectomy for highstage cancer of the prostate. Cancer 47: 1901–1910PubMedCrossRefGoogle Scholar
  6. 6.
    Zincke H, Utz DC (1983) Radical surgery for stage D 1 prostate cancer. Semin Urol 1: 253–260PubMedGoogle Scholar
  7. 7.
    Bagshaw MA (1985) Potential for radiotherapy alone in prostatic cancer. Cancer 55 [Suppl] 9: 2079–2085Google Scholar
  8. 8.
    Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199–1205PubMedGoogle Scholar
  9. 9.
    Brayhack JT, Keeler TC, Kozlowski JM (1984) Carcinoma of the prostate. Hormonal therapy. Cancer 60 [Suppl] 3: 589–601Google Scholar
  10. 10.
    Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  11. 11.
    Winkler HZ, Rainwater LM, Myers RP, Far GM, Therneau TM, Zincke H, Lieber MM (1988) D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63: 103–112PubMedGoogle Scholar
  12. 12.
    Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffinembedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333–1335PubMedCrossRefGoogle Scholar
  13. 13.
    Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323–327PubMedCrossRefGoogle Scholar
  14. 14.
    Winkler HZ, Rainwater LM, Myers RP, Zincke H, Farrow GM, Therneau TM, Lieber MM (1988) Prognostic significance of DNA ploidy and early endocrine therapy in stage D1 prostate cancer (abstract). Annual meeting of the American Urological Association, Boston, Massachusetts, June 3 to 7Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • R. C. Benson
  • H. Zincke

There are no affiliations available

Personalised recommendations